Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Our BPC-157 is lyophilised for maximum shelf stability and cold-pack shipped for same-day dispatch across Canada, typically arriving within 13 business days anywhere in the country
You feel as if you get nothing done by the end of the day
CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
This may cause other ailments such as tiredness, breathing difficulties, weakness, and vomiting
